IDEXX Laboratories, Inc. $IDXX Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 116,995 shares of the company's stock after selling 5,659 shares during the period. California State Teachers Retirement System owned approximately 0.15% of IDEXX Laboratories worth $61,590,848 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. SHP Wealth Management bought a new position in IDEXX Laboratories during the 4th quarter valued at $26,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $25,000. Elevation Wealth Partners LLC lifted its holdings in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock valued at $26,000 after purchasing an additional 32 shares during the last quarter. Wormser Freres Gestion lifted its stake in IDEXX Laboratories by 671.4% during the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company's stock worth $37,000 after purchasing an additional 47 shares during the last quarter. Finally, Arlington Trust Co LLC lifted its stake in shares of IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock worth $32,000 after acquiring an additional 19 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 0.3%

NASDAQ IDXX traded up $1.48 during trading hours on Tuesday, hitting $511.04. 256,165 shares of the company's stock were exchanged, compared to its average volume of 574,235. The firm has a market cap of $40.26 billion, a price-to-earnings ratio of 35.95, a PEG ratio of 2.69 and a beta of 1.54. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The stock has a 50-day simple moving average of $554.49 and a 200 day simple moving average of $565.06. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter last year, the business earned $3.50 earnings per share. The business's revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares of the company's stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.79% of the stock is owned by company insiders.

Analysts Set New Price Targets

IDXX has been the topic of several research reports. Barclays decreased their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 11th. UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Citigroup upped their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings lowered IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average price target of $747.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.